title: PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient.
abstract: BACKGROUND
  Androgen-independent prostate cancer (AIPCA) is a difficult disease to treat. Fulvestrant has shown activity inhibiting estrogen receptor dimerization, and the androgen receptor has been shown to stimulate growth in prostate cancer cell lines.
  
  
  METHODS
  A 79-year-old metastatic prostate cancer patient with AIPCA was treated with fulvestrant acetate with a loading dose strategy. Without recording any significant side effects, the prostate-specific antigen (PSA) level decreased from 154 ng/ml to 0.45 ng/ml 8 weeks after the first treatment administration.
  
  
  CONCLUSIONS
  Fulvestrant was able to reduce the PSA level in this AIPC patient without any toxicity.
authors.affiliation: Department of Medical Oncology, Hospital de Dènia, Alacant, Spain. joanmagasent@telefonica.net
authors.forename: Joan M Gasent
authors.initials: JM
authors.lastname: Blesa
authors.forename: Vicente Alberola
authors.initials: VA
authors.lastname: Candel
mesh_terms: D000085:Acetates / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001859:Bone Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary*; D057176:Compassionate Use Trials; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077267:Fulvestrant; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011944:Receptors, Androgen / Q000235:genetics; D019233:Retreatment
chemical_list: D000085:Acetates; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015507:Drugs, Investigational; D011944:Receptors, Androgen; D000077267:Fulvestrant; D004958:Estradiol; D017430:Prostate-Specific Antigen